CollPlant Biotechnologies Presents on the Use of Novel, Plant-Derived, Recombinant Human Collagen for Anti-Aging Therapies at the Science of Aging Virtual Symposium 2020

Mittwoch, 16.09.20 18:05
CollPlant Biotechnologies Presents on the Use of Novel, Plant-Derived, Recombinant Human Collagen for Anti-Aging Therapies at the Science of Aging Virtual Symposium 2020
Bildquelle: Adobe Stock


PR Newswire





REHOVOT, Israel, Sept. 16, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr. Nadav Orr, Vice President of R&D, presented a corporate overview on the dynamics of cellular aging during Session 3 of the Science of Aging Virtual Symposium 2020. The presentation was titled, "Use of Novel, Plant-Derived, Recombinant Human Collagen for Anti-Aging Therapies."

"We are proud to showcase our plant-derived, recombinant human collagen or rhCollagen platform technology at the exclusive Science of Aging Virtual Symposium 2020 alongside other innovative companies in the aesthetic medicine space," says Dr. Nadav Orr, Vice President of R&D, CollPlant. "Additionally, September is Healthy Aging Month, which presents the ultimate opportunity for us as a company to illuminate our revolutionary Skin Rejuvenation and Breast Implant product pipeline inclusive of our photocurable dermal fillers."

Data presented at the symposium demonstrated smooth injectability and a statistically significant enhancement in proliferation of normal human dermal fibroblasts (nHDF) for cells treated with a combination of hyaluronic acid and rhCollagen relative to HA only following an 8-day treatment period.  

About CollPlant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.

Our products address indications for the diverse fields of tissue repair, aesthetics and organ manufacturing, and, we believe, are ushering in a new era in regenerative and aesthetic medicine.

Our flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. In October 2018, we entered into a licensing agreement with United Therapeutics, whereby United Therapeutics is using CollPlant's BioInks in the manufacture of 3D bioprinted lungs for transplant in humans.

In January 2020, we also entered into a Joint Development Agreement with 3D Systems Corporation, or 3D Systems, pursuant to which we and 3D Systems jointly develop tissue and scaffold bioprinting processes for third party collaborators. Our industry collaboration also includes the Advanced Regenerative Manufacturing Institute, or ARMI.

For more information about CollPlant, visit http://www.collplant.com.

Safe Harbor Statements

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the outbreak of coronavirus; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk and products for medical aesthetics; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk and medical aesthetics products including but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

Contact at CollPlant:

Eran Rotem

Deputy CEO & CFO

Tel: +972-73-2325600

Email: Eran@collplant.com

Sophia Ononye-Onyia, PhD MPH MBA

Founder & CEO, The Sophia Consulting Firm

Tel: +1-347-851-8641

Email: sophia@sophiaconsultingfirm.com

Cision View original content:http://www.prnewswire.com/news-releases/collplant-biotechnologies-presents-on-the-use-of-novel-plant-derived-recombinant-human-collagen-for-anti-aging-therapies-at-the-science-of-aging-virtual-symposium-2020-301132450.html

SOURCE CollPlant





Quelle: PR Newswire




News und Analysen

DGAP-News: Landkreis Ludwigsburg erhält positives Feedback für Corona-Angebot von USU

DGAP-News: USU Software AG / Schlagwort(e): Sonstiges Landkreis Ludwigsburg erhält positives Feedback für Corona-Angebot von USU 30.09.2020 / 11:48 Für den ...weiterlesen

Seite: 1 | 2 | 3 | 4 | 5 | 6 | ... | 15829 ►

Im Fokus

Aktueller Chart
  • +370% Kursgewinn seit Jahresstart!
  • Explodiert die Tesla-Aktie wieder?
  • Jetzt gratis Tesla-Report downloaden!

Value oder Growth? Eine Frage so alt wie die Börse

Value oder Growth? Eine Frage so alt wie die Börse
Die Frage, ob es sinnvoller ist, auf Value- oder auf Growth-Titel zu setzen, ist beinahe so alt wie die Börse selbst. Dabei sind mit der Bezeichnung „Value“ bewährte Unternehmen gemeint, deren Buchwert idealerweise aktuell möglichst niedrig bewertet wird.
© 1994-2020 by boerse.de - Quelle für Kurse und Daten: ARIVA.DE AG - boerse.de übernimmt keine Gewähr